Zenlabs Ethica
- Market cap
- ₹ 18 Cr.
- P/E
- 132.5x
- P/B
- 2.01x
- 52-week range
- 16.5 – 39.99
- ROE
- 0%
- ROCE
- 5.1%
- Dividend yield
- 0%
- Debt / equity
- 1.29
- Sector
- Commercial Services & Supplies
- Industry
- Diversified Commercial Services
- Listed on
- BSE
About
Zenlabs Ethica Limited is an India-based pharmaceutical contract manufacturing company. The Company develops, markets and exports a range of branded drugs including Gastrointestinal disorders, Anti-Diabetics, Anti-Hypertensive Drugs, Anti-Infective, Soaps & Anti-bacterial Drugs, Nutraceuticals, and others. The Company operates in the pharmaceutical’s formulations segment, which primarily includes marketing and distribution of pharmaceutical products. Its divisions include Zenlabs, Coles Pharma and Mega Star. Its product categories include analgesics & anti-inflammatory, skin preparations, neurological disorders, eye, ear and nasal drops, anti-diabetic, anti-depressant, anti-infective, anti-emetic, steroid and anabolic steroids, antihypertensive drugs, anti-allergic, anti-cold and cough syrup, nutraceuticals, antacid, enzymes and appetite stimulant, ayurvedic preparation, git disorders, soap, and other pharmaceutical drugs. Its brands include RBC Red Super Active and Zenovit.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Diversified Commercial Services: 149 companies →Zenlabs Ethica against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)132.5 against a typical 20: pricier than most peers (1st = cheapest).117th of 139
- Sales growth+23.5% against a typical +14.1% from a year earlier.50th of 115
- Profit growth−2,000% against a typical +3.4% from a year earlier.84th of 85
- Share price, 3 months−9.6% against a typical −8.9%.66th of 121
- Size₹ 17.6 Cr. market value against a typical ₹ 68.8 Cr. (1st = largest).99th of 128
Financials
Standalone figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 14 | 16 | 15 | 12 | 13 | 13 | 13 | 11 | 12 | 12 | 11 | 14 |
| Expenses | 14 | 15 | 15 | 12 | 13 | 12 | 12 | 11 | 12 | 12 | 10 | 14 |
| Operating Profit | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | −0 |
| OPM % | 3.1% | 4.4% | 5% | 5% | 4.6% | 5.4% | 5.1% | 4.8% | 3.6% | 4.2% | 2.6% | −2.1% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | −2 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | −2 | 0 | −1 |
| Tax % | 30.8% | 26.7% | 25% | 42.9% | 25% | 33.3% | 43.8% | 20% | 50% | 0% | 114.3% | 3.6% |
| Net Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | −2 | 0 | −1 |
| EPS in Rs | 0.14 | 0.17 | 0.23 | 0.06 | 0.08 | 0.14 | 0.14 | 0.05 | 0.06 | −3.09 | 0 | −0.88 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 12%
- 5 Years
- −4%
- 3 Years
- −11%
- TTM
- −2%
- 10 Years
- −23%
- 5 Years
- −52%
- 3 Years
- −72%
- TTM
- −277%
- 10 Years
- 6%
- 5 Years
- −8%
- 3 Years
- −14%
- TTM
- —
- 10 Years
- 7%
- 5 Years
- 5%
- 3 Years
- 2%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Zenlabs Ethica | ₹ 26.15 | ₹ 18 Cr. | 132.5x | 2x | 0% | — |
| Aurobindo Pharma | ₹ 1,569.30 | ₹ 90,294 Cr. | 26.9x | 2.6x | — | 10.6% |
| Neuland Laboratories | ₹ 18,882.05 | ₹ 24,132 Cr. | 68.6x | 13.5x | — | 21% |
| Pfizer | ₹ 3,610.35 | ₹ 16,513 Cr. | 23x | 4.2x | — | 28.6% |
| Unichem Laboratories | ₹ 470.00 | ₹ 3,309 Cr. | 47x | 1.3x | — | 13.2% |
| Jagsonpal Pharmaceuticals | ₹ 213.00 | ₹ 1,402 Cr. | 33.4x | 5.3x | — | 15.5% |
Management
- Sanjeev Kumar
- Chairman of the Board, Managing Director
- Sanjay Dhir
- Chief Financial Officer
Prices are delayed and for information only. Nothing on this page is investment advice.